BusinessAxsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business UpdateBy Nasdaq OMXMay 8, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric AssociationBy Nasdaq OMXMay 3, 2018, 11:02 AM UTC
BusinessAxsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018By Nasdaq OMXMay 1, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant DepressionBy Nasdaq OMXApr 26, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXApr 24, 2018, 11:01 AM UTC
BusinessAxsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking CessationBy Nasdaq OMXApr 23, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceBy Nasdaq OMXMar 27, 2018, 11:00 AM UTC
BusinessAxsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental NeurotherapeuticsBy Nasdaq OMXMar 12, 2018, 11:00 AM UTC
